

(12) **UK Patent Application** (19) **GB** (11) **2 319 607** (13) **A**

(43) Date of A Publication 27.05.1998

(21) Application No 9624411.6

(22) Date of Filing 23.11.1996

(71) Applicant(s)

Electrophoretics International Plc

(Incorporated in the United Kingdom)

**Coveham House, Downside Bridge Road, COBHAM,
Surrey, KT11 3EP, United Kingdom**

(72) Inventor(s)

Denis Francois Hochstrasser

Christopher Donovan James Pearce

(74) Agent and/or Address for Service

Lucas & Co

**135 Westhall Road, WARLINGHAM, Surrey, CR6 9HJ,
United Kingdom**

(51) INT CL⁶

G01N 33/68 33/53

(52) UK CL (Edition P)

G1B BAD B307

(56) Documents Cited

WO 93/11155 A1

**Biochemical Journal, Vol. 320, No. 2, 1996, pages 563
to 570 Neuroreport, Vol. 6, No. 7, May 1995, pages
1045 to 1049 American Journal of Pathology, Vol. 145,
No. 6, December 1994, pages 1280 to 1284 9th Int.
Congress of Immunol., San Francisco, California, US
A, July 23-29, 1995, ix+742p, No. 49**

(58) Field of Search

UK CL (Edition O) G1B BAD

INT CL⁶ G01N 33/53 33/68

ONLINE: DIALOG/BIOTECH, WPI

(54) **Detection of prion proteins in mononuclear cells**

(57) Prion diseases, in which abnormal prions are implicated, are detected or measured by taking a blood sample from an animal or human and separating therefrom mononuclear cells. The abnormal prions are detected in the cell lysate or after isolating prion protein therefrom by any known technique, especially immunologically using anti-prion protein antibodies and enhanced chemiluminescent assay or immuno-PCR.

GB 2 319 607 A

DIAGNOSIS OF PRION DISEASES

1. Field of the Invention

This invention relates to the diagnosis of prion diseases, being those in which prions are implicated, especially neurodegenerative diseases and more especially bovine spongiform encephalopathy (BSE).

2. Description of the Related Art

It is now well accepted that certain diseases are caused by "proteinaceous infectious particles", termed "prions". For a review, see S.B. Prusiner, Scientific American, 30-37 (January 1995), the disclosure of which in relation to prion diseases is herein incorporated by reference. These diseases include principally neurodegenerative diseases, especially encephalopathies such as BSE in cattle, scrapie in sheep and goats and Creutzfeld-Jakob Disease (CJD) and CJD variants in humans. Prion proteins are present in the host cells of healthy individuals and are called PrP^C. In diseased individuals, an abnormal isoform of the protein (PrP^{Sc}) accumulates in the brain. The abnormal isoform is distinguished from the cellular form by its insolubility and partial resistance to proteases. It appears to be a conformational isomer. Despite the availability of anti-prion protein antibodies which react with prion protein in the brains of diseased animals, no satisfactory test has yet been devised for the early diagnosis of prion diseases in tissue samples from live animals (or humans).

SUMMARY OF THE INVENTION

According to the invention, the above problem is solved by a method which comprises assaying abnormal prion proteins in a sample of mononuclear cells present in the blood. The term "assay" is used herein to cover mere detection (the likely ordinary use envisaged) and a quantative or semi-quantative procedure in which some

estimate is made of the amount of the abnormal prion protein present in the sample. Ordinarily the assay will be immunological, i.e. will depend on an interaction between abnormal prion protein and an antibody thereto. The invention depends for its success on the application of the assay to samples concentrated in the specialised mononuclear cells, which will usually be monocytes.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The method of the invention may be applied to a concentrated sample of mononuclear cells separated from other blood cells. The mononuclear cells include particularly monocytes and macrophages. Monocytes, which originate in the bone marrow, are present in about 6 percent of white blood cells. Their residence time in blood is only 1 or 2 days, after which, as monocytes or macrophages, they squeeze through the cells lining the capillaries of the blood system and migrate into the body tissues.

To practise the present invention, it is necessary to separate white blood cells from red blood cells and the mononuclear cells from polynuclear cells and other white blood cells. The mononuclear cells are lysed, e.g. with buffered detergent. The purpose of such separations is to concentrate the mononuclear cells so that the sample contains a detectable amount of prion protein. Thereafter, it may be desirable to separate the protein components of the sample and to separate the proteins, e.g. by gel electrophoresis or gel filtration chromatography.

The prion proteins present in the mononuclear cell sample (or protein components thereof) are most conveniently detected immunologically. That is, they are reacted in some way with an antibody which is labelled, directly or indirectly.

The term "antibody" as used herein includes polyclonal antiserum, monoclonal antibodies, fragments of antibodies such as Fab and genetically engineered antibodies. The antibodies may be chimeric or of a single species. Anti-prion protein antibodies raised against prion proteins or appropriate short peptides therefrom can be used. They include principally antibodies which react, e.g. by Western blotting or immunohistochemical detection with brain tissue taken from dead animals or humans which or who have died from the prion disease to be diagnosed by the method of the invention or another prion disease where the antibody cross-reacts with the prion protein of that other disease. Thus, BSE or scrapie and deceased humans suffering from CJD or CJD variants may be detected, normally with antibodies raised against the prion protein from the brain tissue of the animal or human suffering from the same disease. Examples are the polyclonal antisera 970 and 971 from the Central Veterinary Laboratory of the UK Ministry of Agriculture, Fisheries and Food, Addlestone, Surrey KT15 8NB, England, anti-prion protein monoclonal antibody 3F4 from R.J. Kacsak et al., J. Virol. 67,3688-3693 (1987) and rabbit anti-prion protein monoclonal antiserum R073 from D. Serban et al., Neurology 40, 110-117 (1990), the disclosures of which in relation to preparation of the antibodies are herein incorporated by reference.

The precise type of the immunological reaction is not critical, but preferably the prion protein is absorbed on a solid phase. Thus, it is conveniently transferred to a membrane and Western-blotted with the antibody. Alternatively, an immunoassay such as an ELISA may be carried out by immobilising the sample on a solid phase.

Western blotting (immunoblotting) may be carried out in any known way. The protein has to be isolated or

at least semi-separated, e.g. by ID-gel electrophoresis. The protein is transferred to a suitable membrane, preferably of nitrocellulose or polyvinylidene difluoride, the membrane is blocked to prevent non-specific adsorptions, e.g. with milk powder. After blocking, the protein can be detected directly or indirectly. Direct detection uses labelled primary antibodies (the anti-prion protein antibodies), but it is more convenient to use unlabelled primary antibodies and to label secondary antibodies which are anti- to the immunoglobulin of the primary antibodies. The antibodies are usually labelled with an enzyme such as peroxidase or alkaline phosphatase, either directly or via a ligand which has a high affinity for a co-ligand, such as biotin, which has a high affinity for streptavidin and avidin. The protein is then conveniently detected by adding an enzyme substrate, e.g. a colour-forming one, to read out the enzyme label or an enzyme-labelled co-ligand plus a substrate for the enzyme if a high affinity type ligand was used.

It may be desirable to digest the protein to be Western blotted with a protease such as proteinase K before it is put on the gel. The abnormal prion protein, being resistant to cleavage by proteinases will then have a higher molecular weight and travel less far on the gel than normal prion protein.

An alternative method of quantifying or detecting the presence of protein is the use of immunoassays, which may be performed on a lysate of the mononuclear cells, on protein components extracted therefrom or on isolated or semi-separated protein. Any known method of immunoassay may be used. An antibody capture assay is preferred. Here, the test sample is allowed to bind to a solid phase, such as a well of a plastics microtitre plate, and the anti-prion protein antibody is then added

and allowed to bind. After washing away unbound material, the presence or amount of antibody bound to the solid phase is determined using a labelled second antibody, as described above. Alternatively, a competition
5 assay could be performed between the sample and a labelled peptide having the same sequence as in a prion protein, these two antigens being in competition for a limited amount of antibody bound to a solid support. The labelled peptide could be pre-incubated with the
10 antibody on the solid phase, whereby the prion protein in the sample displaces part of the peptide bound to the antibody. Alternatively, the two antigens are allowed to compete in a single co-incubation with the antibody. After removal of unbound antigen from the support by
15 washing, the amount of label attached to the support is determined and the prion protein in the sample is detected or measured by a reference to standard titration curves established previously.

The substrate for the enzyme may be colour-forming,
20 fluorescent or chemiluminescent.

It is highly preferable to use an amplified form of assay, whereby an enhanced "signal" is produced from a relatively low level of prion protein to be detected. One particular form of amplified immunoassay is enhanced
25 chemiluminescent (ECL) assay. Here, the antibody is preferably labelled with horseradish peroxidase, which participates in a chemiluminescent reaction with luminol, a peroxide substrate and a compound which enhances the intensity and duration of the emitted light, typically
30 4-iodophenol or 4-hydroxycinnamic acid.

Another preferred form of amplified immunoassay is immuno-PCR. In this technique, the antibody is covalently linked to a molecule of arbitrary DNA comprising PCR primers, whereby the DNA with the antibody attached
35 to it is amplified by the polymerase chain reaction.

See E. R. Hendrickson et al., Nucleic Acids Research 23, 522-529 (1995) or T. Sano et al., in "Molecular Biology and Biotechnology" ed. Robert A. Meyers, VCH Publishers, Inc. (1995), pages 458-460, the disclosures of which in
5 relation to immuno-PCR methods and reagents are herein incorporated by reference. The signal is read out as before.

The following Example illustrates the invention.
"Tween" is a Registered Trade Mark.

10 EXAMPLE

In this Example, all operations are conducted under sterile conditions and an ambient temperature. A 20ml sample of blood is taken from an animal or human suspected to be suffering from a prion disease. The
15 sample is taken using a syringe containing 1 percent of a 5000U/ml heparin preparation.

For each sample to be tested, two sterile 12ml tubes (Falcon 3033) are used. In each tube is placed 4ml of Ficoll-Paque (Pharmacia AB) and 8-9ml of the
20 blood (to fill the tube to the upper mark) are squirted gently down the walls of the tubes. The stoppers of the tubes are flamed to sterilise them and the tubes are then closed. The tubes are centrifuged at 2500 rpm for 15 minutes. During this time, a Falcon tube is prepared
25 which contains 2ml of TC199 Hanks' medium containing 0.35g/ml sodium bicarbonate, but no L-glutamine ("Seromed" F 0635 from Fakola AG), pre-filtered through a 0.22 micrometre "Millipore" filter). After centrifugation, the circular band of monocytes is recovered by use
30 of a Pasteur pipette and placed in 2ml of TC199 Hanks' medium, ready for culture. The volume of the tube is made up to the upper mark with TC199 medium. The cells are washed three times with phosphate - buffered saline (PBS), pH 7.4 and centrifuged for 10 minutes each time
35 at 1500, 1200 and 1000 rpm respectively. After each

wash the cells are re-suspended with a Pasteur pipette. Finally, the cells are suspended in 2.5ml of RPMI 1640 medium containing 2.0g/l sodium bicarbonate, but without L-glutamine ("Seromed" F 1215 from Fakola AG), together
5 with 20 percent AB serum.

To carry out the assay, one mg of mononuclear cell protein samples is solubilized by mixing with 20µl of a solution containing SDS 2% (w/v), 5% (v/v) beta-mercaptoethanol, 10% (w/v) glycerol and Tris-HCl 62.5mM (pH
10 6.8). The mixture is heated at 95° C for 5 min. The proteins are then separated by 1-D SDS-PAGE and transferred onto PVDF membranes using a semi-dry apparatus with 10% methanol and 10mM CAPS as buffer (pH 11) at 50 V for 45 min. The membranes are stained with amido
15 black, scanned and tested with the anti-prion protein. The PVDF membranes are first blocked with a blocking solution (5% (w/v) dry low fat milk, 0.5% (v/v) "Tween 20" and 10mM PBS (pH 7.4)) for 30 min, probed in the same solution containing the primary antibody (anti-
20 prion protein) for 2 h and washed for 3 X 10 min in 10mM PBS (pH 7.4) and 0.5% (v/v) Tween 20. The secondary goat anti-mouse or anti-rabbit antibody (1:100 BAKO) labelled with peroxidase is mixed with the blocking solution. The membranes are soaked in the latter solu-
25 tion for 1 h. and then washed for 4 X 10 min in 10mM PBS (pH 7.4) and 0.5% (v/v) "Tween 20". Protein detection is achieved using enhanced chemiluminescence and x-ray films as described by the manufacturer (Boehringer Mannheim). The membranes can be reprobed 3 to 5 times
30 after stripping. Stripping of the membranes is achieved using a solution containing 2% (w/v) SDS, 200mM DTE and 63mM Tris-acetate (pH 6.7) at 50° C for 30 min and the membranes are washed for 4 X 10 min in 10mM PBS (pH 7.4). All the immunoblotting steps are done in glass
35 cylinders (25cm X 6cm) with a hybridization oven at

25°C.

The following claims define some preferred aspects
of the invention, but should not be construed as detr-
acting from the generality of the invention concepts
5 hereinbefore set forth.

10

15

20

25

30

35

CLAIMS

1. A method of detecting or measuring abnormal prion proteins present in a sample of blood taken from an animal or human suspected of suffering from a prion disease, which comprises separating mononuclear cells present in the blood and detecting or measuring prion proteins present in said cells.
2. A method according to Claim 1, wherein prion proteins are detected or measured immunologically.
3. A method according to Claim 2, wherein the prion proteins are detected or measured using an anti-prion protein antibody which reacts with brain tissue of a dead animal of the same or a cross-reactive species or of a human respectively, said animal or human having died of a prion disease, or with prion protein obtained from said brain tissue.
4. A method according to Claim 2 or 3, wherein the prion proteins are isolated or semi-separated from a lysate of the mononuclear cells and are then Western blotted.
5. A method according to any preceding claim for the detection of BSE from samples of blood taken from cattle.

25

30

35



Application No: GB 9624411.6
Claims searched: 1 to 5

Examiner: Mr S J Pilling
Date of search: 27 February 1997

Patents Act 1977
Amended Search Report under Section 17

Databases searched:

UK Patent Office collections, including GB, EP, WO & US patent specifications, in:
UK Cl (Ed.O): G1B (BAD)
Int Cl (Ed.6): G01N 33/53, 33/68
Other: ONLINE: DIALOG/BIOTECH, WPI

Documents considered to be relevant:

| Category | Identity of document and relevant passage | Relevant to claims |
|----------|--|--------------------|
| A | WO 93/11155 A1 (PROTEUS MOLECULAR DESIGN) see page 20 lines 5 to 7 and page 27 lines 29 to 32. | - |
| A | Biochemical Journal, Vol. 320, No. 2, 1996, L Diomedea <i>et al</i> , "Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes", pages 563 to 570. | - |
| A | Neuroreport, Vol. 6, No. 7, 9 May 1995, V Askanas <i>et al</i> , "Human muscle macrophages express β -amyloid precursor and prion proteins and their mRNAs", pages 1045 to 1049. | - |
| A | 9th International Congress of Immunology; Meeting sponsored by the American Society of Immunologists and the International Union of Immunological Societies, San Francisco, California, USA, July 23-29, 1995, ix + 742p, V Dodelet & N R Cashman, "Prion protein expression in myeloid cell differentiation", Abstract No. 249. | - |
| A | American Journal of Pathology, Vol. 145, No. 6, December 1994, E Sarkozi <i>et al</i> , "Abnormal accumulation of prion protein mRNA in muscle fibers of patients with sporadic inclusion-body myositis and hereditary inclusion-body myopathy", pages 1280 to 1284. | - |

| | | | |
|---|---|---|--|
| X | Document indicating lack of novelty or inventive step | A | Document indicating technological background and/or state of the art. |
| Y | Document indicating lack of inventive step if combined with one or more other documents of same category. | P | Document published on or after the declared priority date but before the filing date of this invention. |
| & | Member of the same patent family | E | Patent document published on or after, but with priority date earlier than, the filing date of this application. |